Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Drug Dev Ind Pharm ; 40(1): 61-5, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23244199

RESUMO

OBJECTIVE: This work deals with the preparation, characterization and in vitro release study of IBU-loaded gel graft copolymer nanoparticles. METHOD: Gelatin (Gel) graft copolymer nanoparticles were prepared using styrene (Sty) and/or 2-hydroxyethyl methacrylate (HEMA) monomers in the presence of potassium persulfate and glutaraldehyde as an initiator and cross-linker, respectively. The prepared nanoparticles as sustained release drug carriers were investigated using the nonsteriodal anti-inflammatory model drug, ibuprofen (IBU). RESULTS: The prepared nanoparticles as sustained release drug carriers were investigated using the nonsteriodal anti-inflammatory model drug, IBU. The prepared Gel/HEMA and Gel/Sty nanoparticles exhibited particles size ranging from 15 to 17 nm and from 0.42 to 5 mm, respectively. The dissolution of IBU in phosphate buffer, pH 7.4, at 37°C from the prepared nanoparticles was evaluated using UV spectroscopy. In addition, the prepared nanoparticles were characterized using Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), transmitting electron microscope (TEM) and zeta potential/particle size analyzer. In vitro dissolution study showed that the dissolution rates of the crosslinked nanoparticles were retarded relative to the uncrosslinked ones. Moreover, the released amount constantly decreases with increasing gluteraldehyde content in the gel nanoparticles. CONCLUSION: Crosslinked gel-based graft copolymers exhibited slow IBU release within six hours. Furthermore, results from different characterization techniques such as TEM, particles size and zeta potential measurements confirmed the formation of pH-responsive gel-graft copolymer nanoparticles.


Assuntos
Portadores de Fármacos/química , Gelatina/química , Ibuprofeno/administração & dosagem , Nanopartículas , Anti-Inflamatórios não Esteroides/administração & dosagem , Anti-Inflamatórios não Esteroides/química , Varredura Diferencial de Calorimetria , Reagentes de Ligações Cruzadas/química , Preparações de Ação Retardada , Composição de Medicamentos , Concentração de Íons de Hidrogênio , Ibuprofeno/química , Metacrilatos/química , Tamanho da Partícula , Polímeros/química , Solubilidade , Espectroscopia de Infravermelho com Transformada de Fourier , Estireno/química , Fatores de Tempo
2.
Int J Pharm ; 426(1-2): 256-262, 2012 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-22310458

RESUMO

A commercial suspension of nanoparticles (Eudragit RS 30D) was used to manufacture a gel for topical application. Gels were prepared by mixing a polycationic polymer (Eudragit(®) RS 30D) and a low molecular weight heparin (LMWH), an antithrombotic agent. Gels formed spontaneously at a ratio of 1:1 as a result of electrostatic interactions between the polyanionic drug and the polycationic polymer. Different types of heparin were used: Bemiparin, Enoxaparin (Lovenox), Nadroparin (Fraxiparin) and Tinzaparin (Innohep). Several LMWH concentrations were tested. Rheological measurements were performed to investigate the gel behavior. Gel formation was confirmed by dynamic rheological measurements as the elastic modulus (G') was higher than the viscous one (G″). The amount of heparin incorporated into the gel matrix was determined. A maximum of incorporation (100%) was reached using a heparin solution of 600 IU/mL. The release kinetics of LMWH from the gel were also studied. Regardless of the LMWH used in the formulation, a biphasic release profile was observed. Accordingly, a burst effect was observed. Afterwards, the release rate became steady. The penetration of the LMWH through the dermal barrier was also investigated.


Assuntos
Resinas Acrílicas/química , Portadores de Fármacos , Fibrinolíticos/administração & dosagem , Heparina de Baixo Peso Molecular/administração & dosagem , Nanopartículas , Administração Cutânea , Animais , Química Farmacêutica , Composição de Medicamentos , Módulo de Elasticidade , Enoxaparina/administração & dosagem , Fibrinolíticos/sangue , Fibrinolíticos/química , Fibrinolíticos/farmacocinética , Géis , Heparina de Baixo Peso Molecular/sangue , Heparina de Baixo Peso Molecular/química , Heparina de Baixo Peso Molecular/farmacocinética , Masculino , Nadroparina/administração & dosagem , Nanotecnologia , Permeabilidade , Coelhos , Ratos , Ratos Wistar , Reologia , Pele/metabolismo , Absorção Cutânea , Solubilidade , Tecnologia Farmacêutica/métodos , Tinzaparina , Viscosidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...